Drugs / GC1130A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06567769 | Nov 2024 → Jun 2027 expected | mucopolysaccharidosis type 3A | GC Biopharma Corp | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GC1130A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06567769 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Heparan N-Sulfatase (rhHNS, GC1130A)” NCT06567769 ↗ |
| Route | Other | “ICV injection” NCT06567769 ↗ |